Table 2.
Biomarker | GOSE | Gender | RPCSQ (total) | Age | RPCSQ (16 cut-off) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spearman ρ | p-Value | n | Spearman ρ | p-Value | n | Pearson's r | p-Value | n | Pearson's r | p-Value | n | Pearson's r | p-Value | n | |
Amyloid β40 | −0.082 | 0.410 | 104 | 0.034 | 0.731 | 104 | −0.007 | 0.948 | 95 | 0.180 | 0.068 | 104 | −0.007 | 0.946 | 95 |
Amyloid β42 | 0.063 | 0.525 | 103 | −0.032 | 0.750 | 103 | −0.015 | 0.889 | 94 | 0.063 | 0.525 | 103 | −0.028 | 0.788 | 94 |
Tau | −0.231 | 0.018 | 105 | 0.252 | 0.010 | 105 | −0.013 | 0.900 | 96 | 0.013 | 0.899 | 105 | −0.026 | 0.799 | 96 |
GOSE, Glasgow Outcome Scale extended; RPCSQ, Rivermead Post Concussion Symptoms Questionnaire. Statistically significant findings are in bold.